Health Care • Biotechnology: Pharmaceutical Preparations
$215.98 ▲ +8.15
(+3.92%)
MKT CAP: $14.02B • VOL: 1.22M
52W L $129 52W H $266
JAZZ // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $4.27B | $4.07B | $3.83B |
| YoY Revenue Growth % | +4.9% | +6.1% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$430.2M | $716.6M | $578.6M |
| Operating Margin % | -10.1% | 17.6% | 15.1% |
| Net Income (GAAP) | -$356.1M | $560.1M | $414.8M |
| EBITDA (Normalized) | -$383.2M | $747.1M | $716.6M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $1.36B | $1.40B | $1.09B |
| Capital Expenditures (CapEx) | $58.8M | $38.1M | $172.5M |
| Free Cash Flow (FCF) | $1.30B | $1.36B | $919.5M |
| FCF Margin % | 30.4% | 33.4% | 24.0% |
| Return on Invested Capital (ROIC %) | -4.7% | 7.3% | 10.2% |
| Cash & Short-Term Equivalents | $1.39B | $2.41B | — |
| Total Debt (Short + Long Term) | $4.33B | $6.08B | $1.74B |
| Total Stockholders' Equity | $4.32B | $4.09B | $3.56B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR JAZZ.